Charles River Laboratories International Inc [CRL] stock is trading at $178.05, up 4.46%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CRL shares have gain 9.55% over the last week, with a monthly amount drifted -8.82%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Charles River Laboratories International Inc [NYSE: CRL] stock has seen the most recent analyst activity on November 17, 2025, when Argus upgraded its rating to a Buy. Previously, Robert W. Baird upgraded its rating to Outperform on November 06, 2025, and kept the price target unchanged to $199. On October 06, 2025, upgrade upgraded it’s rating to Outperform. Barclays upgraded its rating to an Overweight but stick to its price target of $195 on October 02, 2025. Jefferies upgraded its rating to a Buy but $195 remained the price target by the analyst firm on September 09, 2025. Citigroup upgraded its rating to Buy for this stock on July 09, 2025, but kept the price target unchanged to $200. In a note dated May 23, 2025, Redburn Atlantic upgraded a Buy rating on this stock but restated the target price of $182.
Charles River Laboratories International Inc [CRL] stock has fluctuated between $91.86 and $203.01 over the past year. Currently, Wall Street analysts expect the stock to reach $192.8 within the next 12 months. Charles River Laboratories International Inc [NYSE: CRL] shares were valued at $178.05 at the most recent close of the market. An investor can expect a potential return of 8.28% based on the average CRL price forecast.
Analyzing the CRL fundamentals
Charles River Laboratories International Inc [NYSE:CRL] reported sales of 4.02B for the trailing twelve months, which represents a drop of -0.49%. Gross Profit Margin for this corporation currently stands at 0.32% with Operating Profit Margin at 0.03%, Pretax Profit Margin comes in at -0.0%, and Net Profit Margin reading is -0.02%. To continue investigating profitability, this company’s Return on Assets is posted at -0.01, Equity is -0.02 and Total Capital is 0.02. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.83.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 172.86 points at the first support level, and at 167.66 for the second support level. However, for the 1st resistance point, the stock is sitting at 180.90, and for the 2nd resistance point, it is at 183.74.
Ratios To Look Out For
For context, Charles River Laboratories International Inc’s Current Ratio is 1.37. Also, the Quick Ratio is 1.10, while the Cash Ratio stands at 0.17. Considering the valuation of this stock, the price to sales ratio is 2.18, the price to book ratio is 2.57.
Transactions by insiders
Recent insider trading involved Joseph LaPlume, Officer, that happened on Aug 22 ’25 when 400.0 shares were purchased. EVP, Corp Strategy & Develop, LaPlume Joseph W completed a deal on Aug 18 ’25 to sell 800.0 shares. Meanwhile, Former Director WALLMAN RICHARD F bought 22500.0 shares on Aug 18 ’25.
